Centocor’s ustekinumab delayed
This article was originally published in Pharmaceutical Approvals Monthly
FDA pushes Centocor's ustekinumab PDUFA date to December, granting the agency more time to review BLA amendments, the firm announces Aug. 8. Ustekinumab was unanimously recommended by an FDA advisory committee in June for approval for moderate to severe psoriasis, but the panel asked the J&J unit for long-term studies to evaluate cancer risk. The drug, which is aiming for a dosing advantage with a four injections per year regimen, was originally slated for an agency decision in September (1Pharmaceutical Approvals Monthly July 2008, p. 3). According to Centocor, FDA is not seeking additional clinical trials for ustekinumab
You may also be interested in...
So far, the approval trends for new molecular entities and novel biologics in the first half of 2008 suggest that this year’s final tally may look very similar to last year’s record-low approval total.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Interested parties have been consulted, workshop findings noted and online surveys completed; the drafting of Germany’s digital health strategy is now underway.